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Inhibiting the system xC
/glutathione axis
selectively targets cancers with mutant-p53
accumulation
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TP53, a critical tumour suppressor gene, is mutated in over half of all cancers resulting in
mutant-p53 protein accumulation and poor patient survival. Therapeutic strategies to target
mutant-p53 cancers are urgently needed. We show that accumulated mutant-p53 protein
suppresses the expression of SLC7A11, a component of the cystine/glutamate antiporter,
system xC
 , through binding to the master antioxidant transcription factor NRF2. This
diminishes glutathione synthesis, rendering mutant-p53 tumours susceptible to oxidative
damage. System xC
 inhibitors speciﬁcally exploit this vulnerability to preferentially kill cancer
cells with stabilized mutant-p53 protein. Moreover, we demonstrate that SLC7A11 expression
is a novel and robust predictive biomarker for APR-246, a ﬁrst-in-class mutant-p53
reactivator that also binds and depletes glutathione in tumours, triggering lipid peroxidative
cell death. Importantly, system xC
 antagonism strongly synergizes with APR-246 to induce
apoptosis in mutant-p53 tumours. We propose a new paradigm for targeting cancers that
accumulate mutant-p53 protein by inhibiting the SLC7A11–glutathione axis.
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T
he tumour suppressor gene TP53 is mutated in a large
proportion of cancers. The loss of wild-type p53 (wt-p53)
activity and acquisition of oncogenic gain-of-function,
secondary to aberrant accumulation of mutant-p53 (mut-p53)
protein, frequently results in aggressive tumour phenotypes and
poor survival1. Therefore, effective therapies to target mut-p53
cancers are urgently needed.
APR-246 (PRIMA-1met) is the most clinically advanced mut-
p53 targeting agent and has been shown to reactivate wt-p53
apoptotic functions2. This results in potent anti-tumour activity
in preclinical models where drug sensitivity is strongly associated
with levels of accumulated mut-p53 protein3. Recently, studies
have shown that APR-246 can exert additional effects,
particularly through antagonizing the glutathione (GSH) and
thioredoxin reductase system4,5, leading to increased reactive
oxygen species (ROS). This fuels early speculation that there is
potential cross-talk between mut-p53 and redox regulation6.
Mounting evidence indicates that cancer cells produce higher
levels of ROS compared to normal cells, which in turn can
activate mitogenic signalling and promote carcinogenesis7.
However, ROS can be a double-edged sword, as excessive
accumulation leads to oxidative damage and cell death. These
ﬁndings have led to the hypothesis that cancer cells with elevated
ROS are sensitive to further oxidative insults and therefore can be
selectively targeted. Despite compelling preclinical data, human
trials of prooxidants have been disappointing7. Thus, it is critical
to further elucidate the key modulators of redox balance to design
strategies that maximally exploit the redox differential between
normal and cancer cells.
In this study, we explore in detail the mechanisms and
consequences of APR-246-induced oxidative stress. This led us to
uncover a crucial link between mut-p53 and cellular redox
modulation. We demonstrate that high levels of mut-p53,
through binding to NRF2 and impairing its canonical antioxidant
activities, directly promote ROS accumulation in cancer cells.
This creates an inherent predisposition to further oxidative stress
that can be therapeutically harnessed. APR-246 and inhibitors of
the cystine/glutamate antiporter, system xC , take advantage of
this vulnerability to selectively kill mut-p53 cancer cells. In
combination, these agents synergistically deplete mut-p53 cancers
of GSH, leading to overwhelming ROS accumulation and
extensive cell death. Importantly, we show that endogenous
expression of SLC7A11, a key component of system xC , reliably
predicts tumour response to these therapies. Collectively, we
propose a novel strategy to target cancers that accumulate mut-
p53, based on perturbation of the SLC7A11–GSH axis.
Results
APR-246 triggers lipid peroxidation through depleting GSH.
Using oesophageal cancer as a model, we characterized the
mechanisms and consequences of ROS induction by APR-246.
Firstly, we veriﬁed across a panel of normal and cancer cell lines
with differing p53 status (Supplementary Table 1) that treatment
with a lethal dose of APR-246 resulted in higher intracellular ROS
(Fig. 1a). Extending this, we conﬁrmed that APR-246 rapidly
decreases intracellular GSH in mut-p53 cells (Fig. 1b) leading to a
concomitant increase in ROS levels, prior to the onset of apop-
tosis (Supplementary Fig. 1a,b). Furthermore, the pan-caspase
inhibitor Q-VD prevented APR-246-induced apoptosis without
inhibiting ROS elevation (Supplementary Fig. 1c,d). Altogether,
these results suggest that ROS elevation precedes the activation of
apoptotic pathways, and is not merely a consequence of cell
death. Importantly, APR-246-induced ROS and apoptosis could
be prevented by co-culturing with the antioxidants, N-acetyl-
cysteine and GSH-monoethyl ester (Fig. 1c,d; Supplementary
Fig. 1e,f), highlighting ROS and the GSH pathway as key players
in the anti-tumour activity of APR-246.
To determine how APR-246 depletes GSH, we applied mass
spectrometry to show that 2-methylenequinuclidin-3-one (MQ),
the active component of APR-246, reacts with GSH inside cancer
cells (Fig. 1e,f). The resultant adduct (GS-MQ) has signiﬁcantly
reduced capacity to participate in GSH recycling via GSH
reductase (Fig. 1g), a crucial step in maintaining GSH homo-
eostasis. Given that intracellular GSH can detoxify xenobiotics
through formation of GSH-drug conjugates8, we compared
residual GSH levels following APR-246 and chemotherapy
treatments. At equi-efﬁcacious doses, APR-246 depleted GSH to
a greater extent than cisplatin, 5-ﬂuorouracil, epirubicin,
irinotecan and paclitaxel (Supplementary Fig. 1g), further
emphasizing the importance of this phenomenon to the activity
of APR-246.
We next investigated the consequences of APR-246-induced
GSH depletion, and found that ROS accumulates in the
mitochondria (Fig. 2a), a major reservoir for GSH, leading to
lipid peroxidation (Fig. 2b; Supplementary Fig. 2a), mitochondrial
rupture (Fig. 2c) and release of the apoptotic initiator,
cytochrome c (Fig. 2d). Furthermore, using transmission electron
microscopy, we observed a characteristic set of changes in the
mitochondria after APR-246 treatment, beginning with organelle
condensation and disrupted cristae architecture, followed by gross
swelling, loss of outer membrane integrity and eventual rupture
(Supplementary Fig. 2b). Importantly, the cytotoxic effects of
APR-246 could be rescued with trolox, ferrostatin-1 and 2-
mercaptoethanol (Fig. 2e), antioxidants that retard lipid perox-
idation9. Incidentally, these are all potent inhibitors of ferroptosis,
an iron-dependent, caspase independent form of cell death9.
However, the iron-chelator deferoxamine (DFO) did not affect
APR-246 activity (Supplementary Fig. 2c), suggesting that GSH
depletion by APR-246 triggers lipid peroxidative, but not
ferroptotic cell death.
SLC7A11 expression predicts tumour sensitivity to APR-246.
Having established that GSH depletion is an integral mechanism
of APR-246 activity, we set out to identify predictive biomarkers
using a targeted pharmacogenomics approach. On the basis of
our ﬁnding that endogenous GSH levels correlated with APR-246
GI50 (Supplementary Table 1) in our cell line panel (Fig. 3a), we
shortlisted genes involved in GSH synthesis and recycling, and
correlated their mRNA expression with APR-246 sensitivity
(Fig. 3b). Of these, SLC7A11, SLC3A2 and GPX1 were sig-
niﬁcantly associated with drug response. Notably, the two genes
with the strongest correlation, SLC7A11 and SLC3A2, together
encode the cystine/glutamate antiporter system xC , which serves
to import cystine, the rate limiting substrate for the formation of
GSH10. Since SLC3A2 is dispensable for the function of system
xC (ref. 11), we focused our attention on SLC7A11 and found
that while protein and mRNA expression varied widely between
different cell lines (Fig. 3c,d), both correlated with resistance to
APR-246 (Fig. 3e,f). Consistent with this, analysis of multiple
microarray datasets from the NCI-60 cell line panel (a panel of 60
diverse human cancer cell lines used by the National Cancer
Institute for therapeutic development12,13) demonstrated that
SLC7A11 expression correlated more strongly with response to
the APR-246 lead compound PRIMA-1 than any other gene
(Supplementary Fig. 3a,c). Remarkably, this relationship was
evident across all of the nine different tumour types in the NCI-
60 panel including both solid and haematological malignancies,
highlighting the wide spread importance of this ﬁnding.
Importantly, we noted that cell lines with missense TP53
mutations, which are known to be more sensitive to APR-246
and PRIMA-1 (Fig. 3e; Supplementary Fig. 3d) also have lower
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Figure 1 | Glutathione depletion and ROS induction is central to the anti-tumour activity of APR-246. (a) ROS detected using CellROX 6h post 50mM
APR-246 treatment across a panel of oesophageal cell lines. Mean ﬂuorescence unit (MFU)±s.e.m. From here on FLO-1 and JH-EsoAd1 cells were treated
with their GI90 doses: 25 and 40mM of APR-246, respectively. (b) Glutathione (GSH) concentrations post APR-246 treatment in FLO-1 and JH-EsoAd1
cells. (c,d) CellROX (c) and viability (d) analysis post treatment with APR-246 and/or 5mM glutathione-monoethyl ester (GSH-MEE) and/or N-acetyl-
cysteine (NAC) in FLO-1 and JH-EsoAd1 cells assayed at 10 and 96 h, respectively. (e) Structural formula of GS-MQ (left) following reaction of MQ with
GSH. Typical mass spectrometry (MS) pattern of 100 mM GS-MQ (m/z¼445.17 [mþH]) in 0.1% formic acid (right). (f) MS analysis of JH-EsoAd1 cell
lysates collected 10 h post vehicle and APR-246 treatment. (g) Absorbance of 10mM GSH or GS-MQ as measured with the Cayman GSH kit containing
GSH reductase. Paired t-test (a), unpaired t-test (b,g), one-way ANOVA with Dunnett’s multiple comparison post-test (c,d). Error bars¼ s.e.m., n¼ 3 for
all, *Po0.05, **Po0.01, ***Po0.001. See also Supplementary Fig. 1.
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Figure 2 | APR-246 triggers lipid peroxidative cell death through depleting glutathione. (a,b) Detection of mitochondrial ROS using MitoSOX
(a) and lipid peroxidation using C11-BODIPY (b) post APR-246 treatment in FLO-1 and JH-EsoAd1 cells. (c) Transmission electron microscopy of FLO-1 cells
treated with APR-246 for 15 h. Red arrows: mitochondrial membrane rupture. A minimum of 10 cells were examined. Scale bar for  10,000¼ 2mm, for
 80,000¼ 200nm. (d) Cytochrome c released from FLO-1 and JH-EsoAd1 cells measured using ﬂow cytometry 20 h post APR-246 treatment.
(e) Viability of FLO-1 and JH-EsoAd1 cells at 96 h post treatment with APR-246 and trolox (1mM), ferrostatin-1 (Fer-1, 20mM) or 2-merceptoethanol
(2-ME, 100mM). One-way ANOVA with Dunnett’s multiple comparison post-test (e). Error bars¼ s.e.m., n¼ 3 for all, *Po0.05, **Po0.01, ***Po0.001.
See also Supplementary Fig. 2.
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SLC7A11 expression (Fig. 3e,f). To interrogate the functional
relationship between SLC7A11 and cellular sensitivity to APR-
246, we ﬁrstly knocked down SLC7A11 in JH-EsoAd1 p53KO
(endogenous mut-p53 was knocked out using CRISPR/Cas9) and
parental H1299 p53Null cells. In these cells, which are relatively
resistant to APR-246 (ref. 3), we found that inhibiting SLC7A11
expression sensitized them to APR-246 (Fig. 3g; Supplementary
Fig. 3e). Contrastingly, ectopic expression of SLC7A11 in two
APR-246 sensitive mut-p53 lines, JH-EsoAd1 and FLO-1,
induced resistance to APR-246 (Fig. 3h; Supplementary Fig. 3f).
To corroborate these ﬁndings in vivo, we found that endogenous
SLC7A11 expression correlated closely with tumour response to
APR-246 in eight patient-derived xenograft and cell line models
(Fig. 3i). Overall, these results highlight SLC7A11 as a novel
regulator and predictive biomarker of response to APR-246.
Mut-p53 entraps NRF2 and represses SLC7A11 expression.
Given that SLC7A11 expression predicts and regulates tumour
sensitivity to the prototypical mut-p53 reactivator, APR-246, we
next examined the relationship between mut-p53 and SLC7A11.
We found that SLC7A11 mRNA and protein levels inversely
correlated with accumulation of mut-p53 protein across our
oesophageal cell line panel (Fig. 4a,b). Consistent with this,
analysis of multiple TCGA datasets correlating p53 protein
(RPPA) and SLC7A11 mRNA (RNAseq) expression demon-
strated the same relationship (Supplementary Fig. 4a). In support
of these ﬁndings, we observed an increase in SLC7A11 expression
following siRNA knockdown and CRISPR/Cas9 knockout of
endogenous mut-p53 in FLO-1 and JH-EsoAd1 cells, respectively
(Fig. 4c,d). In contrast, ectopic expression of mut-p53 in H1299
p53Null cells decreased SLC7A11 mRNA and protein levels
(Fig. 4e). Collectively, these results illustrate that accumulation of
mut-p53 suppresses SLC7A11 expression.
We next investigated the mechanism by which mut-p53
suppressed SLC7A11 expression. Since mut-p53 loses its capacity
to bind DNA in a sequence-speciﬁc manner, we hypothesized
that direct trans-repression is an unlikely mechanism of SLC7A11
SLC7A11
Tubulin
Mut p53 (missense)
Mut p53 (Splice/Fs/Del)
Wt p53
Mut p53 (missense)
SLC7A11
Mut p53 (Splice/Fs/Del)
Wt p53
Mut p53 (missense)
Mut p53 (missense)
Mut p53 (Splice/Fs/Del)
Mut p53 (Splice/Fs/Del)
Wt p53
Wt p53
*
SL
C7
A1
1 
m
R
N
A
(%
 N
ES
)
SL
C7
A1
1 
m
R
N
A
(%
 N
ES
)
125
100
75
50
25
0
System
GSS
γ-GCS
GSR GPX1GPX4
XC
–20 150
150
150
100
50
0
–50
120
125 siSLC7A11
100
100
75
75
50
50
25
Cell line and patient-derived xenografts
SL
C7
A1
1/
Tu
bu
lin Tu
m
o
u
r 
gr
ow
th
in
hi
bi
tio
n 
(%
)
25
0
High
SLC7A11 protein
Low
0
125 RFP vector
100
75
50
25
0
100 101.0 101.5 102.0 102.5101 102
100
50
0
0 20 40 60 80 100
0.86
0.82 0.002
<0.001
0.66 0.028
0.31 0.308
0.728
0.540
0.12
0.21
0.15
0.08
0.671
0.826G
SH
 (n
mo
l p
er 
ce
ll)
15
10
5
0
0 20 40 60 80
Glu + Cys
APR-246 GI50 correlation E
so
26
OA
CN
1
FL
O-
1
OA
CM
5.1
JH
-Es
oA
d1
OE
19
OE
19
SK
GT
4
OE
33
OA
CP
4C
TE
7
TE
7
NE
S
Es
o2
6
OA
NC
1
FL
O-
1
OA
CM
5.1
JH
-Es
oA
d1
SK
GT
4
OE
33
OA
CP
4C NE
S
Genes
SLC7A11
SLC3A2
GPX1
GCLC
GSS
GPX4
GSR
GCLM
r P-value
γ-Glu–Cys + Gly
100
r=0.666 r=0.862
P<0.001P=0.025
JH-EsoAd1 p53K0 JH-EsoAd1 p53G266E
GSSG
GSH
APR-246 GI50 (μM)
APR-246 (μM)APR-246 (μM)
AP
R
-2
46
 G
I5
0 
(μM
)
Vi
ab
ilit
y 
(%
 Ve
hi
cl
e)
Vi
ab
ilit
y 
(%
 Ve
hi
cl
e)
APR-246 GI50 (μM)
NT
C
siS
LC
7A
11
SLC7A11
Tubulin
35 kDa
52 kDa
SLC7A11
Tubulin
35 kDa
52 kDa
RF
P v
ec
tor
SL
C7
A1
1 c
DN
A SLC7A11 cDNA
SLC7A11 protein
N: (Veh/APR-246) 5/5 4/4 6/64/4
Eso26 PDX1 FLO-1 OE19 PDX4 MKN74 PDX3 PDX2
5/5 12/12 5/5 9/8 
SLC7A11
Tubulin
Es
o2
6
PD
X1
FL
O-
1
OE
19
PD
X4
MK
N7
4
PD
X3
PD
X2
52 kDa
35 kDa
4
3
2
1
0
a b c
d
e
f g h
i
NTC
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regulation by mut-p53. Seminal studies have shown that the
master antioxidant transcription factor, NRF2, intimately reg-
ulates SLC7A11 transcription14,15. We thus searched for evidence
of potential interaction between mut-p53 and NRF2. Firstly,
using genetic knockdown studies, we conﬁrmed that NRF2 does
indeed regulate SLC7A11 transcription in our cell lines
(Supplementary Fig. 4b). Furthermore, we observed that the
expression of multiple NRF2 target genes responsible for
maintaining cellular redox balance (for example, NQO1,
PRDX1, OGGIN1, HMOX1, KEAP1 and SLC3A2) increased
following mut-p53 knockdown and decreased with mut-p53
overexpression (Supplementary Fig. 4c,d). In parallel, we
reviewed the TCGA datasets and identiﬁed a similar inverse
correlation between accumulation of mut-p53 and expression of
NQO1, a canonical target gene of NRF2 (Supplementary Fig. 4a),
suggesting that mut-p53 is able to interfere with NRF2 activity.
Extending this, given that mut-p53 knockdown, knockout
and overexpression did not consistently or signiﬁcantly affect
the mRNA and protein levels of NRF2 (Supplementary Fig. 4e–g),
we performed protein immunoprecipitation studies and
demonstrated that mut-p53 can interact with NRF2 (Fig. 4f;
Supplementary Fig. 4h). Moreover, this protein interaction is
conserved across different tumour types (oesophageal: FLO-1,
Eso26 and OACM5.1, and lung: H1299) and mut-p53 genotypes.
Importantly, chromatin immunoprecipitation analysis identiﬁed
that mut-p53 is recruited along with NRF2 to the SLC7A11
promoter under oxidative stress (Fig. 4g), which in turn
signiﬁcantly impairs the efﬁciency of NRF2-mediated
upregulation of SLC7A11 (Fig. 4h).
Mut-p53 accumulation sensitizes cancer cells to ROS stress. We
next examined the consequences of mut-p53 accumulation on
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cellular redox balance. Across our cell line panel, accumulation of
mut-p53 protein was signiﬁcantly associated with increased basal
ROS levels (Fig. 5a), and decreased endogenous GSH reserves
(Fig. 5b). Consistently, overexpression of mut-p53 in H1299 cells
diminished system xC activity (Fig. 5c) and GSH levels (Fig. 5d),
resulting in heightened sensitivity to ROS stress (Fig. 5e). In
contrast, knockout of mut-p53 in JH-EsoAd1 cells decreased
basal ROS levels (Fig. 5f) and conferred protection against H2O2
(Fig. 5g). These ﬁndings were replicated when SLC7A11 expres-
sion was directly manipulated (Supplementary Fig. 5a–h).
Moreover, we found that cells with mut-p53 accumulation
had signiﬁcantly higher amounts of ROS following APR-246
treatment when compared to cells with low levels or absence of
mut-p53 protein (Fig. 5h,i). Overall, these results establish
that accumulation of mut-p53, through entrapping NRF2
and repressing SLC7A11 expression, sensitizes cells to oxidative
stress.
System xC blockade targets cancers with mut-p53 accumulation.
Since cancer cells with mut-p53 accumulation are vulnerable to
oxidative stress, we next sought to identify potential antioxidative
stress genes which when suppressed, would preferentially kill cancer
cells with stabilized mut-p53. Using a multi-omics approach, we
examined the outcomes of independently knocking down 438
antioxidative stress genes by analysing the Broad Institute’s Project
Achilles dataset (genome-wide shRNA knockdown in 201 cancer
cell lines16) (see Methods). Remarkably, cell lines with missense
TP53 mutations, which typically accumulate mut-p53 protein, are
most sensitive to knockdown of SLC7A11 than any other
antioxidative stress gene (Fig. 6a; Supplementary Data 1).
Importantly, this ﬁnding was consistent across different tumour
types (Fig. 6b). To further validate this, we knocked down SLC7A11
using siRNA in our oesophageal cell line panel (Fig. 6c), and
demonstrated signiﬁcant impairment of viability and clonogenicity
of cells with missense TP53mutations, which are predominantly p53
high and SLC7A11 low expressers (Fig. 6d,e; Supplementary Fig. 6a).
In addition, we showed that erastin and sulfasalazine (SAS), proven
inhibitors of system xC (ref. 9) (Supplementary Fig. 6b,c),
phenocopied our genetic ablation studies (Fig. 6f; Supplementary
Fig. 6d,f). Moreover, mut-p53 overexpression enhanced the
sensitivity of p53Null H1299 cells to SLC7A11 knockdown and to
system xC inhibitors (Fig. 6g,h; Supplementary Fig. 6g), while
knockout of mut-p53 in JH-EsoAd1 cells had the opposite effect
(Supplementary Fig. 6h,i). Altogether, these results illustrate that
system xC antagonists can preferentially kill cancer cells that
accumulate mut-p53 protein.
SLC7A11 blockade and APR-246 synergize to kill mut-p53
tumours. Since APR-246 depletes GSH and system xC blockade
leads to cystine starvation, which in turn impairs GSH synthesis,
we hypothesized that their therapeutic combination would
synergistically target mut-p53 cancer cells. To test this approach,
we applied APR-246 to our oesophageal cell lines following
SLC7A11 knockdown. We found that inhibiting SLC7A11
Baseline ROS
(all mut-p53 cell lines)
1×105
2×105 8×104
6×104
4×104
2×104
1×105
5×104
4×104
JH-EsoAd1
3×104
2×104
1×104
20
15
10
5
0
0
Pa
re
nta
l
Clo
ne
 pa
r
Clo
ne
 do
x-
Clo
ne
1
Clone14
GI50 (μM)
89.34
114.40
151.56
60.87
53.11
49.61
p53KO
p53KO p53G266E p53KO
p53G266E
p53G266E
Clone7
Clone1
Clonal dox-
Clonal  par
Parental
Clo
ne
7
Clo
ne
14
Pa
re
nta
l
Clo
ne
 pa
r
Clo
ne
 do
x-
Clo
ne
1
Clo
ne
7
Clo
ne
14
0.0 0.5 1.0 1.5
8×104
6×104
4×104
2×104
0
0.0 0.5
mut-p53
low
Low
mut-p53
High
protein
mut-p53
low
mut-p53
high
mut-p53
high
H1299 H1299
*** **
*
*
* *
*
*
125 20
15
10
5
0
100
75
50
125
R175H
R273H
Par p53Null
100
75
50
25
25
0
125
100
75
50
25
0 0 0
0
100 101
H2O2 (μM)
H2O2 (μM)
102 103
100 101 102 103
Pa
r p
53
Nu
ll
R1
75
H
R2
73
H
Pa
r p
53
Nu
ll
R1
75
H
R2
73
H
 mut-p53/actin  mut-p53/actin
Ce
llR
OX
 
M
FU
 p
er
 c
el
l
Ce
llR
OX
 
M
FU
 p
er
 c
el
l
Ce
llR
OX
 
M
FU
 p
er
 c
el
l
Ce
llR
OX
 
M
FU
 p
er
 c
el
l
G
SH
 (n
mo
l p
er 
ce
ll)
G
SH
 (n
mo
l p
er 
ce
ll)
Vi
ab
ilit
y 
(%
 Ve
hi
cl
e)
Vi
ab
ilit
y 
(%
 Ve
hi
cl
e)
G
lu
ta
m
at
e 
re
le
as
e 
(%
 pa
r)
1.0 1.5
r=0.646 r=0.522
P=0.049P=0.031
Baseline GSH
(all mut-p53 cell lines)
Baseline ROS
(JH-EsoAd1)
Baseline GSH
(H1299)
APR-246-induced ROS
(all mut-p53 cell lines)
APR-246-induced ROS
(JH-EsoAd1)
a b
gf
c
h i
d e
Figure 5 | Mut-p53 accumulation sensitizes cancer cells to oxidative stress. (a,b) Correlation of mut-p53 protein (normalized to b-actin) with ROS
(a) and glutathione (GSH) (b) levels under basal growth conditions for all mut-p53 cancer cell lines used in this study. For further analysis cell lines were
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expression signiﬁcantly enhanced the efﬁcacy of APR-246, par-
ticularly against cancer cells with mut-p53 accumulation (Fig. 7a),
resulting in synergistic induction of ROS and apoptosis (Fig. 7b,c;
Supplementary Fig. 7a). Furthermore, both SAS and erastin
strongly synergized with APR-246 to inhibit mut-p53 cancer cells.
This effect was most pronounced in cells with missense TP53
mutations expressing high mut-p53 protein (Fig. 7d,e;
Supplementary Fig. 7b). To validate that this synergistic inter-
action is indeed dependent on mut-p53 and SLC7A11 expression,
we next demonstrated that these drug combinations were more
effective in H1299 cells overexpressing mut-p53 compared to the
p53Null parental line (Fig. 7f; Supplementary Fig. 7c). In contrast,
overexpression of SLC7A11 in mut-p53 FLO-1 cells abolished the
synergistic activity between system xC inhibitors and APR-246
(Fig. 7g; Supplementary Fig. 7d). Mechanistically, we showed that
system xC blockade in conjunction with APR-246, synergistically
depleted intracellular GSH, resulting in mitochondrial ROS
accumulation, lipid peroxidation and ultimately apoptotic cell
death (Fig. 7h–k; Supplementary Fig. 7e–h).
To extend these ﬁndings in vivo, we generated inducible
shSLC7A11 constructs in OE33 and FLO-1 cells using a dual
ﬂuorescence reporter system (Fig. 8a; Supplementary Fig. 8a).
These hairpins efﬁciently knocked down SLC7A11 and had
signiﬁcant inhibitory activity alone or in combination with
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Supplementary Fig. 6.
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APR-246 in vitro (Supplementary Fig. 8b–j). In FLO-1 xenografts,
we found that SLC7A11 knockdown signiﬁcantly enhanced the
anti-tumour activity of APR-246 (Fig. 8b,c; Supplementary
Fig. 8k), leading to synergistic reduction of intratumoral GSH
levels and improved animal survival (Fig. 8d,e). Consistent with
this, the combination of SAS with APR-246 at tolerated doses
(Supplementary Fig. 8l,m) also conferred greater anti-tumour
activity than single agents alone (Fig. 8f). Importantly,
these ﬁndings were reproduced in a PDX model of mut-p53
high-expressing oesophageal cancer (Fig. 8g–i; Supplementary
Fig. 8n–o). Analysis of these tumours revealed markedly reduced
proliferation and increased apoptosis (Fig. 8j). Collectively, these
studies demonstrate the therapeutic potential of combining
system xC inhibitors with APR-246 to synergistically target
cancer cells with mut-p53 accumulation.
Discussion
Here, we propose a new paradigm for targeting mut-p53 cancers
based on speciﬁc perturbations of the system xC and GSH axis.
Our results highlight four key aspects.
First, we demonstrated that APR-246, the prototypical mut-
p53 reactivator, induces lipid peroxidative cell death through
GSH depletion. Although previous studies reported that APR-246
can deplete GSH4,17, the mechanism and consequences of this has
not been fully elucidated until now. Here, we demonstrated that
MQ, the active component of APR-246 (ref. 18), reacts with
GSH in cancer cells to form a thio-ether that is non-reducible by
GSH reductase, a crucial step in the recycling of functional GSH.
Ultimately, this leads to ROS accumulation, particularly in the
mitochondria, resulting in lipid peroxidation, mitochondrial
rupture and the release of cytochrome c, triggering apoptosis.
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(g) Viability at 96 h post treatment with 7.5mM APR-246 and/or 200 mM SAS in FLO-1 cells with either SLC7A11 or red ﬂuorescence protein (RFP)
overexpression. (h–k) GSH (h), MitoSOX (i), C11-BODIPY (j) and Annexin-V/PI (k) analysis of FLO-1 cells treated with 7.5mM APR-246 and/or 0.5 mM
erastin or 200mM SAS. GSH, MitoSOX, C11-BODIPY and Annexin-V/PI were assayed at 15, 24, 24 and 48 h post treatment, respectively. For b,c,f–k the
dose of APR-246, erastin or SAS was deliberately chosen to have low cytotoxicity on its own to highlight the combinatory effect. One-way ANOVA with
Dunnett’s multiple comparison post-test (b,c,e,f,h,i,k), unpaired t-test (g). Error bars¼ s.e.m., n¼ 3 for all, *Po0.05, **Po0.01, ***Po0.01. See also
Supplementary Fig. 7.
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Given that GSH is the predominant ROS-scavenger in cells, and
the source of reducing equivalents for many redox modulating
enzymes such as peroxidases, peroxiredoxins and thiol
reductases7, the loss of GSH signiﬁcantly impairs cellular
response to oxidative stress. Furthermore, recent studies have
demonstrated that GSH depletion can directly activate
lipoxygenases and suppress GPX4 activity to trigger lipid
peroxidation and apoptosis19,20. In summary, GSH depletion
and lipid peroxidation are integral to the anti-tumour activity of
APR-246.
Second, we identiﬁed that expression of SLC7A11, a key
component of system xC that imports cystine for the formation
of GSH, is a novel and robust predictive biomarker of tumour
response to APR-246. Speciﬁcally, cells with low SLC7A11 levels
proved the most sensitive to APR-246. In this way, our study
uniﬁes two key aspects of APR-246 activity: redox modulation
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Figure 8 | System xC
 antagonists synergize with APR-246 in vivo. (a) Example ﬂuorescence imaging of mice bearing FLO-1 xenografts transduced with a
doxycycline (dox)-inducible dual ﬂuorescent vector with shSLC7A11 cloned in (top). Western blot of FLO-1 xenografts 72 h post dox (Food: 600mg kg 1,
water: 2mgml 1) induction to assess the extent of knockdown using two hairpins (sh) against SLC7A11 (Bottom). (b,c) Growth curves of FLO-1 tumours
transduced with shSLC7A11_1 (b) and shSLC7A11_2 (c) hairpins in mice treated with APR-246 (100mg kg 1, daily) and/or dox for 28 days. n¼ 5 per group.
(d) Kaplan–Meier plot of time to reach 1,500mm3 tumour volume in mice bearing FLO-1 tumours transduced with shSLC7A11_1 and treated according to
conditions detailed in b. (e) Intratumoral GSH levels in FLO-1 xenografts transduced with shSLC7A11_2 at 28 days post treatment. (f) Growth curves of
FLO-1 xenografts in mice treated with either vehicle (0.9% saline, daily, n¼ 7), APR-246 (100mg kg 1, daily, n¼ 7), sulfasalazine (SAS, 6mg, twice daily,
n¼ 6) or APR-246 and SAS (n¼ 6) for 28 days (top). Body weight at 28 days post treatment as a percentage change from baseline (bottom). Ethically
acceptable weight loss is deﬁned by the Peter MacCallum Cancer Centre Animal Experimentation Ethics Committee aso20% compared to pre-treatment
body weight (within the dotted lines). (g) Growth curves of Patient-derived xenograft 4 (PDX4) in mice treated with the same drug regimen as (f) for 14
days. Vehicle: n¼ 9, all other groups: n¼ 8. (h) Representative western blot of PDX4 demonstrating the accumulation of mut-p53 protein. (i) Intratumoral
GSH levels in PDX4 at 14 days post treatment with drug regimens detailed in g. (j) Representative H&E, Ki67 and Cleave caspase 3 staining of PDX4
tumours (left) and their respective quantiﬁcation (right). Scale bars¼ 100mm. Grey shading: treatment period. One-way ANOVA with Dunnett’s multiple
comparison post-test (b–g,i,j). Error bars¼ s.e.m., *Po0.05, **Po0.01, ***Po0.01. See also Supplementary Fig. 8.
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and mut-p53-dependent killing of cancer cells21. Our ﬁnding that
SLC7A11 knockdown in p53Null models sensitized cells to APR-
246, while SLC7A11 overexpression in mut-p53 models generated
drug resistance, indicates that the therapeutic activity of APR-246
is dependent not only upon mut-p53 status, but also on the basal
level of SLC7A11 expression and intracellular GSH.
Our studies elucidated a novel and fundamental reciprocal
relationship between SLC7A11 expression and mut-p53 accumu-
lation (Fig. 9). Critically, we demonstrated that suppression of
SLC7A11 transcription results from mut-p53 binding and
interfering with the activity of the master antioxidant transcrip-
tion factor NRF2, a mechanism which is separate from the
transcriptional regulation of SLC7A11 by wt-p53 described by
Jiang et al.22. Through mut-p53 deregulation of SLC7A11 and
consequent depletion of intracellular GSH, leading to ROS
accumulation, cells are sensitized to APR-246. In contrast, cells
that are p53 null or wild-type have relatively higher levels of
SLC7A11 expression, and are therefore resistant to APR-246
treatment. In this way, our study resolves the apparent conﬂict
within the literature reporting variability in p53-dependent
activity and the extent of functional p53 reactivation by APR-
246 (refs 17,23,24).
An interesting additional perspective related to these ﬁndings is
that overexpression of c-Myc, which is a known up-regulator of
SLC7A11 (ref. 25), has recently been found to induce APR-246
resistance26. Similarly, we expect that other factors that modulate
SLC7A11 levels, such as NRF2 (ref. 27), ATF4 (ref. 14) and
CD44v (ref. 28), may also inﬂuence drug response. There is a
worldwide consensus that reliable predictive biomarkers are
critical to the success of personalized cancer medicine29. With
new clinical trials of APR-246 commencing in multiple tumour
streams2, our discovery of SLC7A11 expression as a robust
companion biomarker, in addition to mut-p53 status, for APR-
246, may facilitate selection and enrichment of patients with mut-
p53 tumours who are most likely to respond to APR-246 therapy.
Third, we discovered that mut-p53 accumulation sensitizes
cancer cells to oxidative stress, secondary to impaired NRF2
activity, and that these cancer cells can be selectively targeted
using system xC inhibitors. There is increasing evidence that
aberrant accumulation of mut-p53 leads to gain-of-function
activities in cancer cells30. In line with this, a recent study found
that missense p53 mutants cooperate with NRF2 to inhibit
multiple anti-tumour pathways in cancer cells by upregulating
the proteasome machinery31. Here, we demonstrate that this
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Figure 9 | Model representation of mut-p53 entrapment of NRF2 and its implications for cellular redox balance and therapeutic intervention. (a) In the
absence of mut-p53 accumulation, NRF2 is able to transcriptionally regulate cellular redox balance by binding to antioxidant responsive elements (ARE) on
antioxidative stress (AOS) genes. A crucial component of NRF2-mediated redox regulation is the transactivation of SLC7A11, a key component of the
glutamate (Glu)/cystine (Cys) antiporter, system xc
 (Sxc ), resulting in maintenance of intracellular glutathione (GSH) reserves. (b) Cells with no mut-
p53 accumulation have sufﬁcient GSH reserves, and can mount a normal NRF2-mediated defence against oxidative stress, such as that induced by APR-
246 (active compound: MQ). Therefore, these cells are relatively resistant to APR-246. (c) In cancer cells with mut-p53 accumulation, mut-p53 entraps
NRF2 and impairs its canonical transcriptional activity, resulting in suppressed expression of SLC7A11 and other AOS genes. This reduces GSH reserves and
increases resting levels of ROS. Although these cells are tolerant of this, they are susceptible to further oxidative stress and genomic instability. (d) Cancer
cells with mut-p53 accumulation are therefore highly sensitive to system xc
 inhibitors (for example sulfasalazine (SAS) and erastin) and APR-246. In
combination, these agents synergistically deplete mut-p53 cancer cells of GSH, resulting in signiﬁcant oxidative stress and massive cell death.
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gain-of-function programme has a signiﬁcant weakness. By
binding to NRF2 and suppressing its canonical transcriptional
ability to regulate cellular redox balance, mut-p53 directly
decreases GSH reserves and increases basal ROS levels, thereby
predisposing cancer cells to further oxidative stress (Fig. 9a,c).
While a moderate increase in ROS is tolerated and may even be
advantageous for survival6, excessive ROS accumulation leads to
cell death7. Since normal cells can mount an optimal NRF2-
mediated response to oxidative stress (Fig. 9b), we propose that
accumulation of mut-p53 in cancer cells, through its repressive
effects on NRF2 activity and SLC7A11 expression, creates an
‘Achilles heel’ that can be exploited by further inhibition of
system xC (Fig. 9d). This approach differs from treating
oncogenic addiction32, whereby cancer cells are sensitive to the
inactivation of an overexpressed oncogenic driver. Indeed, we
clearly demonstrate that cancer cells with high SLC7A11 levels
were the least responsive to system xC inhibition. Importantly,
the Broad Institute’s Project Achilles data indicate that
knockdown of SLC7A11, but not any other antioxidative stress
genes, results in killing of cancer cells with stabilized mut-p53.
This suggests that beyond supplying cystine for GSH synthesis,
system xC may participate in other processes that mut-p53 is also
reliant upon. Therefore, elucidating these processes and how they
can be exploited will aid in developing further strategies to target
mut-p53 cancer cells.
Fourth, having identiﬁed that mut-p53 cancer cells are highly
sensitive to system xC inhibition, we next rationalized novel drug
combinations to enhance mut-p53 speciﬁc killing of cancer cells.
Here, we demonstrated that combining system xC blockade with
APR-246 at relatively low doses, selectively and synergistically
depleted mut-p53 cancer cells of GSH, leading to signiﬁcant
lipid peroxidation and induction of massive apoptosis (Fig. 9d).
On the basis of these ﬁndings, we propose that other system
xC inhibitors such as erastin analogs33 and sorafenib34, should
also effectively synergize with APR-246. Indeed, in a recently
completed Phase I trial of APR-246 in patients with
haematological malignancies, it was noted that the addition of
APR-246 to a patient receiving concurrent sorafenib resulted in
complete remission of their acute myeloid leukaemia35. This
provides proof-of-concept that combining system xC inhibitors
with APR-246 is clinically translatable and may potentially have
signiﬁcant therapeutic efﬁcacy against mut-p53 malignancies.
In summary (Fig. 9), our study demonstrates that accumula-
tion of mut-p53 entraps NRF2 and represses SLC7A11 expres-
sion. This renders mut-p53 cancer cells susceptible to oxidative
stress. As single agents, APR-246 and system xC inhibitors
exploit this vulnerability to selectively target mut-p53 cancer cells
in a synthetic lethal-like fashion. In combination, these agents
synergize to further deplete GSH, leading to overwhelming ROS
accumulation and cell death. Moreover, we demonstrate that
SLC7A11 expression is a reliable predictive biomarker for tumour
response to these therapies. This, and the fact that APR-246 and
system xC inhibitors have been safely trialled in humans36,37,
should facilitate rapid translation of our ﬁndings to improve
treatment outcomes for patients with mut-p53 cancers.
Methods
Compounds and reagents. APR-246 and GS-MQ were provided by Aprea
Therapeutics (Solna, Sweden). Cisplatin, 5-ﬂuorouracil, epirubicin, irinotecan and
paclitaxel were from Hospira. GSH-MEE was from Cayman Chemicals. 2-mer-
ceptoethanol and H2O2 were from Merck. Erastin was from SelleckChem. GSH,
NAC, trolox, ferrostatin-1, Q-VD, DFO and SAS were from Sigma-Aldrich.
Parental cell lines. HEK-293T, H1299, OE33 and OE19 cells were from ATCC.
FLO-1, OACM5.1, Eso26, SKGT4, OACP4C and TE7 cells were provided by
Rebecca Fitzgerald (University of Cambridge, UK). JH-EsoAd1 cells were a gift
from James Eshleman (John Hopkins University, MD, USA). MKN74 cells were
obtained from Alex Boussioutas (Peter MacCallum Cancer Centre, Australia).
Immortalized human oesophageal epithelial cells (NES) were provided by Rhonda
Souza (University of Texas Southwestern Medical Centre, TX, USA). OANC1 cells
were derived in our laboratory38. TE7 and OACP4C were classiﬁed as p53Null
controls (Supplementary Table 1). All cell lines were authenticated by short tandem
repeat analysis using the PowerPlex 16 genotyping system (Promega) and
conﬁrmed mycoplasma free by PCR (Cerberus Sciences, Australia).
Cell cultures. All cells were maintained at 37 C with 5% CO2. Unless otherwise
speciﬁed, all culture media contained 10% fetal bovine serum supplemented with
50Uml 1 penicillin and 50mgml 1 streptomycin (Life Technologies). NES cells
were maintained in modiﬁed MCDB-153 medium3. HEK-293T, FLO-1 and
OANC1 cells were grown in DMEM containing 2.5mM L-glutamine and 4.5 g l 1
D-glucose (Life Technologies). All remaining cell lines were cultured in RPMI 1640
medium containing 2.5mM L-glutamine (Life Technologies). Unless otherwise
speciﬁed, the following seeding densities per well/dish were used: 96-well plates:
5 103 cells (FLO-1, SKGT4 and OE33), 1.5 104 cells (OE19) and 1 104 cells
(all others). Twenty-four-well plates: 2.5 104 cells (FLO-1, SKGT4 and OE33)
and 5 104 cells (all others). Six-well plates: 1.3 105 cells (FLO-1, SKGT4 and
OE33) and 2.6 105 cells (all others). Overall, 6 cm dishes: 2 105 cells (FLO-1,
SKGT4 and OE33) and 4 105 cells (all others). Overall, 10 cm dishes: 4 105 cells
(FLO-1, SKGT4 and OE33) and 8 105 cells (all others).
TP53 mutational analysis by Sanger sequencing. Genomic DNA was extracted
using the QIAamp DNA Blood Mini kit (Qiagen). Cycle sequencing was performed
on a 3130 Genetic Analyzer using the BigDye Terminator v3.1 kit (Life Technol-
ogies). PCR conditions and primer sequences are detailed in Supplementary
Table 2.
Western blot analysis. Homogenized tissues or cells were lysed at 4 C in RIPA
buffer (1mM EDTA, 1% NP-40, 0.5% sodium deoxychlorate, 0.1% SDS, 50mM
sodium ﬂuoride, 1mM sodium pyrophosphate in PBS) mixed with protease and
phosphatase inhibitors (Roche). Equal amounts of protein were boiled, resolved by
SDS-PAGE and transferred to polyvinylidene diﬂuoride membranes. Membranes
were incubated in blocking buffer (5% skim milk, 0.1% Tween20 in Tris-buffered
saline) for 1 h and probed overnight with primary antibody at 4 C. Blots were
rinsed thrice (0.1% Tween20 in Tris-buffered saline, 5min each), followed by
incubation with peroxidase-conjugated secondary antibody (Dako) for 2 h at room
temperature. Proteins were detected using Western Lightening Enhanced Chemi-
luminescence (PerkinElmer) or ECL Plus Western blotting substrate kit (Ther-
moFisher Scientiﬁc). Antibodies are detailed in Supplementary Table 3. Protein
densitometric analysis was undertaken using ImageJ software (http://ima-
gej.nih.gov/ij/). Extended western blots are available in Supplementary Fig. 10.
Gene expression with quantitative RT-PCR. Following RNA extraction (RNeasy
kit, Qiagen), reverse transcription (Transcriptor First Strand cDNA Synthesis Kit,
Roche) and SYBR-green RT-PCR (Lightcycler 480, Roche), gene expression was
normalized to GAPDH and analysed using the DDCt method. Primer sequences are
detailed in Supplementary Table 4.
Mutant-p53 overexpression. p53Null H1299 cells were transduced to stably
express either the R273H or R175H p53 mutants as per established protocols39.
Single cell clones were generated following G418 selection to ensure uniform
mutant-p53 expression by western blotting.
TP53 knockout using CRISPR/Cas9 technology. TP53 knockout JH-EsoAd1 cell
line was generated as previously described3. Brieﬂy, a dual lentiviral vector
expression system consisting of a constitutive Cas9 endonuclease (FUCas9) and an
inducible sgRNA (FGT1-UTG) vector, linked to a mCherry and GFP reporter
respectively, were utilized to perform CRISPR/Cas9-mediated TP53 knockout. Two
sgRNA sequences were designed to target exon 4 (GGCAGCTACGGTTTC
CGTCT) and 5 (GAGCGCTGCTCAGATAGCGA) of TP53 using MIT CRISPR
software (http://crispr.mit.edu) and subsequently cloned into BsmBI restriction
sites on FGT1-UTG. Lentiviral particles were produced from HEK-293T cells using
Lenti-X (Clontech) packaging mix according to manufacturer’s instructions. JH-
EsoAd1 cells were transduced with FUCas9 and sorted for mCherry-positive cells
followed by transduction with FGT1-UTG and sorted for GFP-positive cells.
sgRNA induction with doxycycline (2mgml 1) was undertaken for 72 h before
single cell sorting to generate clonal cell lines for each sgRNA. p53 status was
veriﬁed by western blot and TP53 knockout conﬁrmed by MiSeq sequencing.
SLC7A11 knockdown using shRNA. Short hairpin mediated knockdown of
SLC7A11 in FLO-1 and OE33 cells were performed by cloning SLC7A11-speciﬁc
shRNA into a lentiviral tetracycline-inducible expression vector containing the
optimized miR-E backbone (LT3GECIR)40. This system incorporates the mCherry
and turbo-GFP reporters for transduction and induction respectively. FLO-1 and
OE33 cells were transduced with LT3GECIR, sorted for mCherry-positive cells and
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induced with doxycycline (2mgml 1) for 72 h. The 2 (of 8) most efﬁcient shRNA
constructs (TGGAGTTATGCAGCTAATT and GAGGTCATTACACATATAT),
as determined by FACS, RT-PCR and western blotting, were chosen for further
experiments. A hairpin targeting the renilla gene was also constructed as above for
use as a control.
SLC7A11 overexpression. SLC7A11 was ectopically expressed in FLO-1, JH-
EsoAd1 and H1299 cells using the GE Dharmacon Precision LentiORF pLOC
lentiviral vector. In this system, the open reading frame SLC7A11 has been cloned
downstream of the CMV promoter and contains turbo-GFP as a reporter gene. The
turbo-RFP gene in place of SLC7A11 was used as a control. Following transduction,
GFP-positive FLO-1, JH-EsoAd1 and H1299 cells were sorted. The expression of
SLC7A11 was measured using RT-PCR and western blotting.
Genetic knockdown using siRNA. Cells were reverse transfected with 40 nM p53,
NRF2, SLC7A11 or non-targeting control siRNA pools (siGenome Smartpool,
Dharmacon) using Lipofectamine RNAiMax solution (Life Technologies) accord-
ing to the manufacturer’s guidelines. Knockdown efﬁciency was assessed by
RT-PCR and western blotting. siRNA sequences are detailed in Supplementary
Table 5.
Cell viability assay. Cell viability studies were conducted in 96-well format and
assayed using AlamarBlue (Life Technologies) reagent as per the manufacturer’s
instructions. Fluorescence was measured using a FLUOstar OPTIMA microplate
reader (BMG Labtech).
Clonogenic survival assay. FLO-1, JH-EsoAd1, OACP4C and TE7 cells were
seeded at 1 103 cells per well in 6-well plates. OACP4C were cultured for 10 days,
whilst the others were grown for 7 days, followed by ﬁxing with 6% glutaraldehyde
and staining with 0.5% crystal violet. Discrete colonies (450 cells per colony) were
counted using MetaMorph software (Molecular Devices).
Apoptosis assay. Cells were collected from 24-well plates, spun down and
incubated in darkness at 4 C with 0.5% annexin-V-APC antibody (BD Pharmigen)
and 100mgml 1 propidium iodide dissolved in annexin-V binding buffer (1M
CaCl, 5M NaCl, 1M HEPES). At least 1 104 events were recorded by FACS (BD
FACSCanto II, BD Bioscience) and analysed using Flowlogic software (Inivai
Technologies).
Cytochrome c release assay. Cytochrome c release from the mitochondria was
assayed as previously described41. Brieﬂy, all cells were collected from 24-well
plates, washed with PBS and permeabilized with 0.05% digitonin (Sigma-Aldrich,
10mgml 1 in PBS with 100mM KCl) until495% of cells were blue as determined
by trypan blue exclusion. Cells were ﬁxed immediately in 4% paraformaldehyde for
20min at room temperature, washed thrice with PBS, incubated for 1 h in blocking
buffer (3% BSA, 0.5% saponin in PBS) and probed overnight at 4 C with anti-
cytochrome c antibody (BD Pharmigen 556432, 1:200 in blocking buffer).
Subsequently, cells were washed twice with PBS, incubated at room temperature for
1 h with AF-488 anti-mouse secondary antibody (ThermoFisher Scientiﬁc, 1:200 in
blocking buffer) and analysed by FACS (BD FACSCanto II).
ROS detection. Mitochondrial-speciﬁc and generalized cellular ROS were detected
using MitoSOX Red and CellROX Deep Red reagents respectively (ThermoFisher
Scientiﬁc). ROS sensors (5 mM) in phenol-red free media were applied to cells in
96-well plates for the entire study duration. ROS-induced ﬂuorescence was
quantitated using a Cellomics ArrayScan VTI HCS reader (ThermoFisher Scien-
tiﬁc) and normalized to cell number.
Lipid peroxidation detection. Lipid peroxidation was detected using C11-BOD-
IPY(581/591) dye (ThermoFisher Scientiﬁc). Cells were incubated with C11-
BODIPY (5mM) in 24-well plates for deﬁned periods. All cells were collected, spun
down, washed with PBS, resuspended in phenol-red free medium, and analysed
using FACS (BD LSRFortessa BD Bioscience). At least 1 104 events were
recorded.
Intracellular glutathione assay. Total intracellular GSH from tissues or cells
(10 cm dishes) were assayed using the Cayman Chemicals Glutathione Kit as per
the manufacturer’s instructions. GSH concentration was calculated from an
internal standard curve and normalized to tissue weights or total cell number as
determined from parallel plates.
Glutamate release assay. System xc activity was assessed by measuring extra-
cellular release of glutamate from H1299 cells. Overall, 20,000 cells were seeded
into 96-well plates. The next day, cells were washed with PBS and incubated for 3 h
in 50ml of choline buffered solution (137.5mM choline chloride, 5.36mM KCl,
0.77mM KH2PO4, 0.71mM MgSO4.7H2O, 1.1mM CaCl2, 10mM D-glucose and
10mM HEPES, pH 7–7.5 at 37 C) containing 600 mM L-cystine±40mM erastin or
1mM SAS. Extracellular glutamate was detected using the Amplex Red glutamate
release assay kit (Molecular Probes) as per the manufacturer’s instructions. Of note:
as the glutamate released by system xc is Naþ -independent, Naþ was substituted
with choline in the reaction buffer to increase the speciﬁcity of this assay for
measuring system xc activity42.
Protein immunoprecipitation. Four million H1299 mut-p53R273H cells or 5 106
FLO-1, Eso26 and OACM5.1 cells were seeded in 15 cm dishes. The next day, cells
were collected in ice cold PBS, pelleted and sonicated in NP-40 lysis buffer (50mM
Tris pH 8, 150mM NaCl, 5mM EDTA, 0.5% NP-40) with protease inhibitors
(Roche). An aliquot of lysate was removed for input sample prior to incubation
with Protein A-Sepharose beads (Invitrogen). Immunoprecipitations were per-
formed with anti-NRF2 antibody (Cell Signaling Technology, clone D1Z9C), anti-
p53 antibody-agarose conjugate (Santa Cruz Biotechnology), IgG (Santa Cruz
Biotechnology) or Protein A-Sepharose only. Beads were washed ﬁve times in NP-
40 lysis buffer and once in lysis buffer without NP-40 then boiled in 2.5 sample
buffer (125mM Tris-HCl pH 6.8, 5% SDS, 25% glycerol, 2.5% 2-mercaptoethanol,
0.005% bromophenol blue). Samples were analysed by western blotting with anti-
NRF2 (clone D1Z9C) and anti-p53 (clone DO-1) antibodies.
Chromatin immunoprecipitation. H1299 mut-p53R273H cells were seeded as per
protein immunoprecipitation and treated the next day with 50 mM H2O2 for 4 h.
Protein–DNA conjugates were cross-linked by the addition of 1% formaldehyde for
10min. Cells were collected in PBS and sequentially lysed in buffer 1 (50mM
HEPES pH 7.5, 140mM NaCl, 1mM EDTA, 10% glycerol, 0.5% NP-40, 0.25%
TritonX-100), buffer 2 (10mM Tris pH 8, 200mM NaCl, 1mM EDTA, 0.5mM
EGTA) and buffer 3 (10mM Tris pH 8, 100mM NaCl, 1mM EDTA, 0.5mM
EGTA, 0.1% sodium deoxycholate, 0.5% N-lauroylsarcosine) with protease inhi-
bitors (Roche). Lysates were sonicated followed by precipitation of cellular debris
with 1% Triton X-100. An aliquot of lysate was removed for input sample prior to
immunoprecipitation as described above. Beads were washed ﬁve times in LiCl
wash buffer (50mM HEPES pH 7.5, 500mM LiCl, 1mM EDTA, 1% NP-40, 0.7%
sodium deoxycholate), once in TE/NaCl wash buffer (10mM Tris pH 8, 1mM
EDTA, 50mM NaCl) and protein–DNA conjugates eluted by incubating at 65 C
in 50mM Tris pH 8 with 10mM EDTA and 1% SDS, followed by a further 6 h
incubation at 65 C. DNA was recovered by phenol:chloroform:isoamyl alcohol
(25:24:1, Sigma-Aldrich) and ethanol/sodium acetate precipitation following
digestion with 0.2mgml 1 RNAseA (Promega) and 0.2mgml 1 Proteinase K
(Promega). Samples were analysed by RT-PCR using primers bordering a cluster
of three NRF2 consensus sites in the SLC7A11 promoter (forward 50–30 :
AGGCTTCTCATGTGGCTGAT; reverse 50–30 : AGAATTGAGAGCACGA
TGCA).
High performance liquid chromatography and mass spectrometry. Synthetic
GS-MQ or APR-246 treated de-proteinized JH-EsoAd1 cell lysates were resolved
on an ODS-Hypersil C18 HPLC column (2.1 100mm, 5 mm, Hewlett-Packard) in
10mM NH4HCO3 pH 8, using a 0–80% acetonitrile gradient over 10min. Flow
rate was 0.1mlmin 1. Fractions of 25ml were collected and acidiﬁed with 2%
formic acid for mass spectrometric analysis. All analyses were done on an Agilent
6220 ESI-TOF mass spectrometer. Mass spectrometry data was acquired and
reference mass corrected via a dual-spray electrospray ionization (ESI) source.
Mass spectra were created by averaging the scans across each peak and background
subtracted against the ﬁrst 10 s of the total ion current. Acquisition was performed
using the Agilent Mass Hunter Acquisition software version B.02.01 (B2116.30)
and analysed using Mass Hunter version B.03.01. GS-MQ was detected at a
445.17m/z peak.
Light microscopy. Phase contrast images were acquired using an AMG EVOS FL
(Advanced Microscopy Group) microscope. Four independent ﬁelds were taken
per experimental condition. Representative images are shown.
Transmission electron microscopy. FLO-1 and JH-EsoAd1 cells were seeded in
10 cm dishes. The following day, cells were treated with vehicle (H2O) or APR-246
(FLO-1: 25mM and JH-EsoAd1: 40mM) for 15 and 24 h. Cells were collected in
PBS, gently spun down, ﬁxed in 2% paraformaldehyde, 2.5% glutaraldehyde in
0.1M sodium cacodylate buffer before washing in 0.1M sodium cacodylate buffer
and post-ﬁxing in 1% osmium tetroxide in 0.1M sodium cacodylate buffer. Fol-
lowing ﬁxation, cells were dehydrated through a graded series of alcohols and
embedded in Spurrs Resin. Ultrathin sections were cut with a diamond knife using
a Leica Ultracut S ultra-microtome (Austria), stained with both methanolic uranyl
acetate and lead citrate before viewing in a JEOL 1011 transmission electron
microscope (Japan) at 60 kV. Images were recorded with a MegaView III CCD
cooled digital camera (Soft Imaging Systems, Germany) at  10,000– 80,000
magniﬁcation. At least 10 mitochondria were examined per treatment group.
Representative images are shown.
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Combination drug studies. To quantify the synergistic activity of APR-246 with
system xC inhibitors, the GI50 dose of single agents was ﬁrstly determined by
ﬁtting the Hill equation using Prism 6 software (Graphpad). Cells were then treated
for 96 h with combinations of APR-246 and system xC inhibitors over a range of
concentrations held at a ﬁxed ratio and based on the GI50 of each drug. The
highest and lowest combination ratios were three times and 1/10th the GI50,
respectively. Combination indexes (CI) at 50%, 75% and 90% reduction in cell
viability was determined using CalcuSyn v2 (Biosoft) where synergism: CIo0.9,
antagonism: CI41.1 and additive effect: 0.9rCIr1.1 (ref. 43).
Xenograft models and treatment. All animal experiments were approved by the
Peter MacCallum Cancer Centre (PMCC) Animal Experimentation Ethics Com-
mittee and undertaken in accordance with the National Health and Medical
Research Council Australian Code of Practice for the Care and Use of Animals for
Scientiﬁc Purposes. For cell line xenografts, 5 million cells suspended in 100 ml of
1:1 PBS and Matrigel (BD Bioscience) were subcutaneously injected into the ﬂank
of 6 weeks old, female nude or NOD-SCID IL-2RgKO (NSG) mice. Patient-derived
xenografts (PDX) were established as previously described and implanted sub-
cutaneously on the dorsum of NSG mice44. The collection and use of human tissue
was approved by the Human Research Ethics Committee at PMCC. Informed
consent was received from all patients. Tumour volume was assessed unblinded
with caliper measurements every 3–4 days, and calculated using the formula
(lengthwidth2)/2. Mice were randomized to treatment cohorts once tumours
reached 80mm3. For all experiments, APR-246 was administered at 100mg kg 1
daily and SAS at 6mg per mouse twice daily. Saline was given to control animals.
All treatments were delivered by intraperitoneal injections. For shRNA
experiments, shSLC7A11 was induced with doxycycline chow (600mg kg 1,
Specialty Feeds, Australia) and water (2mgml 1, Sigma-Aldrich) available ad
libitum. Three days following doxycycline induction, mice were imaged using the
Maestro2 (CRI) ﬂuorescence imaging system to detect GFP expression. Tumours
were subsequently monitored as above. All mice were killed when tumours reached
1,500mm3 for survival studies or 6 h after the last treatment dose for biomarker
studies. Tumours were photographed, weighed and partitioned for GSH,
immunohistochemical, RT-PCR and western blot analysis. Tumour growth
inhibition was calculated with the formula [1-(Tf-Ti)/mean(Cf-Ci)] 100, where
Tf, Ti and Cf, Ci represents ﬁnal (f) and initial (i) tumour volume of drug treated
(T) and control (C) animals respectively. On the basis of the sample size
calculations, n¼ 5 per group will detect a 50% difference with a power of 80% and
an alpha error of 5%.
Immunohistochemistry. Sections from formalin-ﬁxed parafﬁn embedded tissues
were stained with Ki67 (ab16667, Abcam) and anti-cleaved caspase-3 (9664, Cell
Signalling Technology) antibodies, detected using the Envision Plus system (Dako),
and viewed on a BX51 microscope (Olympus). Three representative images per
tumour were captured at 20 magniﬁcation and analysed using MetaMorph
software.
TCGA data analysis. The cBioportal for Cancer Genomics (www.cbioportal.org)
was used to analyse the relationship between p53 protein expression and SLC7A11
or NQO1 mRNA expression across all available RPPA and RNAseq datasets.
RNAseq data was linearized, and a protein z-scoreZ1 was deﬁned as high p53
expression.
NCI-60 pharmacogenomic analysis. The Pattern comparison function from
CellMiner 1.6 (http://discover.nci.nih.gov/cellminer/analysis.do) was used to
identify novel predictors of PRIMA-1 (NSC 281668) sensitivity across the NCI-60
cancer cell line panel13. The mean-normalized transcript intensity z-scores from 5
Agilent expression arrays were correlated with PRIMA-1 GI50 (mM following anti-
log transformation). Genes with a |r|40.3 are considered by the National Cancer
Institute’s Therapeutics Development programme to be potentially signiﬁcant
predictors of drug sensitivity13, and thus were shortlisted for further analysis.
Project Achilles multi-omics data analysis. Project Achilles v2.4 (www.broa-
dinstitute.org/achilles) is a genome-wide shRNA screen performed in 216 cell lines.
Cells were transduced with ﬁve shRNAs per gene. The abundance of remaining
individual shRNAs relative to an initial reference pool was quantiﬁed by next-
generation sequencing, and reﬂects each cell line’s sensitivity to knockdown of that
gene16. Gene-level shRNA scores were derived by calculating the median from
individual shRNA scores. A gene-level shRNA score below 0 indicates reduced cell
viability, equal to 0 indicates no effect on viability, and above 0 indicates enhanced
viability. The TP53 status for each cell line was annotated from the Cancer Cell
Line Encyclopaedia (www.broadinstitute.org/ccle) and the IARC TP53 Database
(p53.iarc.fr) (Supplementary Fig. 9). Fifteen cell lines were excluded from the ﬁnal
analysis due to unknown or conﬂicting TP53 status. In addition, a comprehensive
list of 548 antioxidative stress genes were compiled from several sources: (1)
Chromatin immunoprecipitation sequencing of NRF2 under basal and ROS-
induced conditions as identiﬁed by Chorley et al.27, (2) known human genes with
functionally validated antioxidant responsive elements as reviewed by Chorley
et al.27 and (3) Gene Ontology designated ROS responsive genes45. These
antioxidative stress genes were interrogated using Project Achilles v2.4. to identify
candidate genes, which when inhibited would preferentially reduce the viability of
missense mut-p53 cancer cells (which typically accumulate mut-p53 protein)
compared with cells that are p53 wild-type or null (non-missense p53, which
typically have low or absent p53 levels). The extent of preferential killing was
calculated by subtracting the median gene-level shRNA score of missense mut-p53
cell lines from the median gene-level shRNA score of non-missense p53 cell lines,
such that a value above 0 indicates preferential killing of missense mut-p53 cells,
and a value below 0 indicates preferential killing of non-missense p53 cells.
Statistics. Data were analysed with Student’s t-test or ANOVA with Tukey’s/
Dunnett’s multiple comparison post-test. Survival differences were compared using
Kaplan–Meier log-rank analysis. Correlation between two groups was evaluated by
the Pearson’s test. Statistical analyses were performed using Prism 6 (Graphpad)
with Po0.05 considered statistically signiﬁcant.
Data availability. The datasets analysed within this study are available from
cBioportal for Cancer Genomics (www.cbioportal.org), CellMiner 1.6 (http://dis-
cover.nci.nih.gov/cellminer/analysis.do), Project Achilles v2.4 (www.broadin-
stitute.org/achilles), Cancer Cell Line Encyclopedia (www.broadinstitute.org/ccle),
IARC TP53 Database (p53.iarc.fr), Nucleic Acids Research online (DOI: https://
doi.org/10.1093/nar/gks409) and Oncotarget online (DOI: 10.18632/onco-
target.1658). The authors declare that all other data supporting the ﬁndings of this
study are available within this paper and its supplementary information ﬁles.
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